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Abstract
Background: Clinical studies implying the sunitinib multi-kinase inhibitor have led to disappointing results for
breast cancer care but mostly focused on HER2-negative subtypes. Preclinical researches involving this drug mostly
concern Triple Negative Breast Cancer (TNBC) murine models. Here, we explored the therapeutic efficacy of
sunitinib on a PyMT-derived transplanted model classified as luminal B (HER2-positive) and monitored the response
to treatment using both in vivo and ex vivo approaches.
Methods: Tumour-induced animals were treated for 9 (n = 7) or 14 (n = 8) days with sunitinib at 40 mg/kg or with
vehicle only. Response to therapy was assessed in vivo by monitoring glucose tumour metabolism and hypoxia
using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) and [18F]fluoromisonidazole ([18F]FMISO) Positron Emission
Tomography (PET). After primary tumour excision, ex vivo digital microscopy was performed on treated and control
samples to estimate vascular density (CD31), apoptosis (Tunel), proliferation (Ki-67), Tumour-Associated Macrophage
(TAM) infiltration (F4/80), metabolism (GLUT1) and cellular response to hypoxia (HIF1 alpha). The drug impact
on the metastasis rate was evaluated by monitoring the PyMT gene expression in the lungs of the treated and
control groups.
Results: Concomitant with sunitinib-induced tumour size regression, [18F]FDG PET imaging showed a stable
glycolysis-related metabolism inside tumours undergoing treatment compared to an increased metabolism in
untreated tumours, resulting at treatment end in 1.5 less [18F]FDG uptake in treated (n = 4) vs control (n = 3)
tumours (p < 0.05). With this small sample, [18F]FMISO PET showed a non-significant decrease of hypoxia in treated
vs control tumours. The drug triggered a 4.9 fold vascular volume regression (p < 0.05), as well as a 17.7 fold
induction of tumour cell apoptosis (p < 0.001). The hypoxia induced factor 1 alpha (HIF1 alpha) expression was
twice lower in the treated group than in the control group (p < 0.05). Moreover, the occurrence of lung metastases
was not reduced by the drug.
Conclusions: [18F]FDG and [18F]FMISO PET were relevant approaches to study the response to sunitinib in this
luminal B (HER2-positive) model. The sunitinib-induced vascular network shrinkage did not significantly increase
tumour hypoxia, suggesting that tumour regression was mainly due to the pro-apoptotic properties of the drug.
Sunitinib did not inhibit the metastatic process in this PyMT transplanted model.
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Background
Based on encouraging preclinical data, the sunitinib drug,
a multi-kinase inhibitor, has been investigated in several
clinical studies in association with various cytotoxic drugs
but led to disappointing results in breast cancer patients.
Classically, breast cancers are classified according to the
expression levels of the estrogen (ER) and progesterone
(PR) receptors, and of the human epidermal growth factor
receptor 2 (HER2) oncogene. The large majority of studies
with sunitinib involved advanced and heavily treated
breast cancer focusing on the HER2-negative (or trastuzu-
mab (TZM) insensitive) subtypes (phase I [1], phases II [2,
3], phases III [4–6]). Interestingly, Burstein et al. adminis-
tered sunitinib alone and detected superior overall re-
sponse rate (ORR) for the HER2-positive subtype (25 % vs
11 % in the whole population) [7]. Moreover, two re-
cent reports focusing on HER2-positive breast cancers
found an improved ORR in adding sunitinib to regi-
mens based on TZM with or without docetaxel admin-
istration [8, 9].
The breast cancer classification is now reconsidered in
the light of global gene expression analyses of human
biopsies leading to six identified subtypes: luminal A and
B, basal-like, claudin-low, HER2-enriched and normal
breast like [10, 11]. A detailed panorama of the relation-
ships between the histological- and the transcriptomic-
based classifications has been recently published [12]. In
this context, the breast cancer patient care is evolving as
it is expected that the efficacies of chemotherapeutic
regimens should depend on the considered subtype.
In the case of sunitinib, many preclinical studies were
performed using various Triple Negative Breast Cancer
(TNBC) mouse models, and all found that the drug de-
layed the tumour growth at doses ranging between 20
to 60 mg/kg/day. Interestingly, sunitinib treatment in-
duced tumour regression in a MCF7 xenograft model
[13], which is a typical luminal A cancer [14], as well as
on a MMTV-v-Ha-Ras transgenic model [15], which
has been classified as luminal B [16]. Among the breast
cancer diversity, the luminal subset represents mainly
the ER+ group, for which an endocrine therapy is
recommended. The luminal A cancers are defined as
ER+ PR+ HER2- and low Ki-67 whereas luminal B car-
cinomas are ER+ HER2+ or ER+ PR+/− HER2- and
high Ki-67 [17, 18]. The luminal A cancers present a
relatively good outcome, but the luminal B tumours,
which represent 10 to 20 % of all breast cancers, are
associated with a poor prognosis and identification of
new therapeutic options for this subtype is still very
challenging. Thus, as most anterior preclinical studies
with sunitinib focused on TNBC models, we investi-
gated here its efficacy in a luminal B-type breast cancer
model combining in vivo PET and ex vivo histochemical
analyses of tumours.
For this purpose, we used the MMTV-PyMT murine
model whose oncogenesis is induced by expression of the
polyoma virus middle T oncoprotein under control of the
Mouse Mammary Tumour Virus (MMTV) promoter
(PMID: 1312220). Following the recommendations of
Varticovski et al. [19] about the limitations of using gene-
tically engineered mouse models in preclinical studies, we
generated a transplanted orthotopic and syngeneic model
from the original transgenic mice. In order to characterize
the therapy response to sunitinib in the PyMT model, we
then performed in vivo Positron Emission Tomography
(PET) with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG)
and [18F]fluoromisonidazole ([18F]FMISO) radiotracers,
which allow to monitor tumour glucose metabolism and
hypoxia respectively. Furthermore, in vitro analyses were
used to quantify the chemotherapy impact on several
cancer-associated parameters, namely vascularization
(CD31), apoptosis (TUNEL), proliferation (Ki-67), hypoxia
(HIF1 alpha), TAM infiltration (F4/80), metabolic activity
(GLUT1) and metastasis.
Methods
Animal studies were approved by the animal ethics com-
mittee “Comité d'EThique en Expérimentation Animale”
(CETEA DSV n°44) under reference 12–036 and con-
ducted in accordance with the Directives of the European
Union.
Tumour removal and preparation of cell suspensions
FVB/N-Tg (MMTV-PyMT)634Mul/J (PyMT) 12-weeks-
old mice were used as tumour donor. Aseptically collected
mammary tumours from PyMT mice were minced and
immersed in cold Dulbecco's Modified Eagle's Medium
(Sigma, USA). Mechanical cell dissociation was performed
using Medicon disposable chambers (BD bioscience,
USA). The cell suspension was then progressively filtered
using Filcon filters with pore sizes of 500 μm, 200 μm and
70 μm (BD bioscience). Finally, cells were aliquoted in
freezing medium (Life Technologies, USA) and stored in
liquid nitrogen.
Tumour implantation and monitoring
After freezing medium removal and enumeration, the tu-
mour cells were directly inoculated, without any in vitro
culture step, in the mammary fat pad of the posterior
nipple in FVB mice. The tumour volumes were calcu-
lated using calliper measurements and the approximated
formula for a prolate ellipsoid, given by:
Volume mm3
  ¼ Length mmð Þ  Width2 mm2   =2:
To evaluate drug toxicity, body animal weights were
also monitored.
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Chemotherapy
Two sets of mice were used in this study. For the main
set A, 7 animals were implanted with 3 million viable
cells. PyMT tumours were allowed to grow for 21 days.
The mice were randomized into treated (n = 4) and con-
trol (n = 3) groups. The treated one received per os a
daily dose of sunitinib at 40 mg/kg in 20 mM dimethyl
sulfoxyde (DMSO, Sigma). The control group received
only the DMSO solution. Drug administration was per-
formed during 9 consecutive days.
To further explore the neoadjuvant therapy effects on
the metastatic incidence, we extended primary tumour
growth and treatment times before mammary tumour
surgical resection. Thus, a secondary set B of treated (n
= 4) and control (n = 4) mice was obtained implanting
400 000 viable cells. Treatment began at day 25 post im-
plantation. It continued for 14 days until resection at
day 39. For both sets A and B, the primary tumours
were surgically removed after treatment and the mice
were kept alive for 60 supplementary days before eu-
thanasia to analyse the lungs for metastasis content.
[18F]FDG and [18F]FMISO positron emission tomography
[18F]FDG and [18F]FMISO PET scans were performed
on mice from set A at days 0 and −1 respectively prior
to treatment and at days 5 and 6 of treatment. 15 min
long PET acquisitions were performed 60 min after
[18F]FDG injection and 90 min after [18F]FMISO injec-
tion. PET data were corrected for attenuation, scatter
and radioactive decay and reconstructed using a two
dimensional ordered-subset expectation maximization
(2D-OSEM) algorithm after Fourier rebinning, with a
voxel size of 0.5 × 0.5 × 0.8 mm3 (sofware ASIPro VM™,
CTI Concorde Microsystems). Radioactivity uptake in re-
gions of interest (ROIs) was measured using BrainVISA
4.0 and Anatomist 4.0.2 (CEA/Neurospin/SHFJ, France)
and expressed in Standardized Uptake Value (SUV) calcu-
lated using:
SUV ¼ ½percent of injected dose per gram %ID=gð Þ
 body mass gð Þ=100:
Histochemistry
Primary tumours from set A of animals were fixed in zinc
solution (BD bioscience) and included in paraffin. Series
of tissue sections were sequentially cut. For blood vessels,
macrophages and cellular hypoxia sensor labelling, the slides
were immersed in toluene and progressively rehydrated.
Endogenous peroxidases and biotin were blocked with 3 %
hydrogen peroxide solution (Sigma) and biotin blocking kit
(Life technologies) respectively. Rat anti CD31 (Pharmin-
gen, USA), rat anti F4/80 (Caltag, UK) and rabbit anti Hyp-
oxia Inducible Factor 1 alpha (HIF1 alpha, LSBio, USA)
were used as primary antibodies for each labelling respect-
ively. Biotin-goat anti rat IgG (Life technologies) was used
as secondary antibody for vascular and macrophage stain-
ing. The tyramide signal amplification (TSA) system (Per-
kin Elmer, USA) was then used following manufacturer’s
instructions. For HIF1 alpha labelling, HRP-goat anti rabbit
IgG (Life technologies) was incubated as secondary anti-
body. For cellular proliferation and Glucose transporter 1
(GLUT1) expression labelling, paraffin removal was per-
formed using heated PT module buffer pH8 (Fischer Scien-
tific, USA). As above, after the blocking steps, the slides
were incubated with goat anti Ki-67 (Santa Cruz, USA) or
rabbit anti GLUT1 (Neomarker, USA) for each labelling re-
spectively. Secondary detection reagents were biotin-rabbit
anti goat IgG (Life technologies) followed by TSA system
for Ki-67 or HRP-goat anti rabbit IgG (Life technologies)
for GLUT1. After 3-3'–diamino-benzidine (DAB, Sigma)
revelation, counterstaining was performed with
hematoxylin (Sigma) and slides were mounted with Eukitt
(Sigma). For late apoptosis staining, terminal deoxynucleo-
tidyl transferase dUTP nick end labelling (TUNEL, Pro-
mega, USA) was used according to the manufacturer’s
protocol. Slides were then mounted with ProLong Gold
Antifade Reagent containing 4',6'-diamidino-2-phenylindole
(DAPI, Life technologies).
Microscopy image acquisition and analysis methods
The set of tissue sections uniformly sampling the whole
volume of each tumour was entirely scanned at high reso-
lution (0.37 μm per pixel) using an AxiObserver Z1 (Zeiss,
Germany). The resulting brightfield image series were ana-
lysed using the CellProfiler software [20]. After a colour
deconvolution step, the segmentation of each structure of
interest was based on a constant labelling-dependent
threshold. A filtering step was added for size-based vessel
clustering. Logic diagrams of the processing pipelines are
available as supplementary data (see Additional files 1 and
2). The DAB-labelled surface areas and whole hematoxylin
areas were measured by the software. The consistency of
the automatic segmentation was controlled visually on the
original images supplemented with the outlines of identi-
fied objects. Whole tissue sections fluorescently labelled
with the TUNEL method were acquired using two excita-
tion/emission filter sets: 365/445 nm for DAPI and 470/
525 nm for TUNEL staining. TIF-format images were
processed using the ImageJ software [21], yielding the
total area corresponding to fluorescent pixels above a
given constant threshold. The measured areas were multi-
plied by the distance between each tissue slide to get vol-
ume estimates.
Quantitative real time polymerase chain reaction (qRT-PCR)
The whole-lung tissue ribonucleic acids (RNA) were ex-
tracted using the total RNA isolation kit (Macherey-
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Nagel, Germany) following manufacturer’s instructions.
RNA was reverse transcribed using SuperScript II (Life
technologies) with random primer hexamers. On a Light-
Cycler 1.5 (Roche, Switzerland), a subsequence of the
PyMT cDNA was amplified in Master SYBR Green I mix
(Roche) using the previously described primers [22]. The
housekeeping myelin protein zero (P0, MPZ) gene was
used as an internal control. A relative quantification ana-
lysis was performed applying the delta-delta Ct method.
Statistical analyses
For statistical analysis, unpaired Student t-tests were
performed using GraphPad Prism software. A p-value of
0.05 or less was interpreted as statistically significant. In
all graphs, values are reported as mean ± one standard
deviation (SD).
Results
Sunitinib-induced mammary tumour regression on the
PyMT model
In set A of mice, the mean tumour volume measured by
calliper was 209 ± 38 mm3 (n = 7) just before treatment
(day 21). During the treatment phase until day 30, the
tumours of the control group continued to grow up to
418 ± 62 mm3 (n = 3), while the size of the treated tu-
mours decreased down to 109 ± 24 mm3 (n = 4) (Fig. 1a,
p < 0.001). In set B of mice, the mean tumour volume
measured by calliper was 115 ± 9 mm3 when treatment
started (day 25, n = 8). At resection (day 39), tumour
volumes were 282 ± 43 mm3 in the control group (n = 4)
and 57 ± 11 mm3 in the treated group (n = 4) (Fig. 1b, p
< 0.0001). The mouse weights corrected for their tumour
weight (Fig. 1c-d) were not significantly different be-
tween the treated and control arms.
Effect of sunitinib administration on [18F]FDG and
[18F]FMISO in vivo uptakes
PET monitoring was only performed for set A of mice.
In the reconstructed images, the signal appeared more
prominent in the tumour, bladder and heart compared
to the rest of the body (Fig. 2a). At randomization,
[18F]FDG uptakes expressed in SUV were similar in both
groups. In the control group, the tumour [18F]FDG uptake
was 1.4 greater after 5 days than at randomization, from
Fig. 1 In vivo therapy model follow-up. a-b Tumour volume evolution, as measured by calliper, for sets A and B of mice respectively (set A: n = 3
for control, n = 4 for treated/set B: n = 4 for each group). c-d Mice body weight evolution for sets A and B respectively. In all graphs, arrows
indicate the first day of sunitinib treatment
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1.2 ± 0.1 to 1.6 ± 0.3 (n = 3) in SUV, although the differ-
ence was not statistically significant (NS). In the treated
group, the [18F]FDG uptake remained stable during sunitinib
administration, from 1.1 ± 0.2 to 1.1 ± 0.2 (n= 4) in SUV
(NS). As a result, after 5 days of treatment, the [18F]FDG
uptake was significantly lower, by a factor of 1.5 (p < 0.05), in
the treated versus the control tumours (Fig. 2b).
The [18F]FMISO PET images exhibited an enhanced
contrast in the tumour and intestine regions (Fig. 2c). At
randomization, [18F]FMISO tumour uptake was not sig-
nificantly different between the group to be treated (1.2
± 0.2 in SUV, n = 3) and the control group (0.8 ± 0.1 in
SUV, n = 3), although lower in the control group. After
6 days of sunitinib or vehicle only administration, the
tracer uptake remained stable in the control group (0.9
± 0.2 in SUV, n = 3) and decreased in the treated one
(0.9 ± 0.4 in SUV, n = 3), thus reducing the initial differ-
ences between the two groups (Fig. 2d).
Ex vivo evaluation of sunitinib incidence on PyMT tumour
hallmarks
Digital microscopy analysis was exclusively performed on
set A of mice. In the control and treated groups, the mean
hematoxylin volumes estimated using digital microscopy
were 126 ± 6 (n = 3) and 45 ± 20 mm3 (n = 4) respectively
(p < 0.01). The nine day sunitinib treatment induced a 4.9
fold regression of the vascular volume reported to the
hematoxylin volume, with values of 3.6 ± 1.8 % (n = 3) and
0.7 ± 0.05 % (n = 4) in the control and treated groups re-
spectively (p < 0.05) (Fig. 3a). The sunitinib treatment in-
duced a reduction of the large vessel proportion (from
31.3 ± 15.6 % in the control group to 8.3 ± 4.0 % in the
treated group, p < 0.05), an increase of the small size
vessels (from 33.4 ± 16.5 % in the control group to 61.0 ±
11.1 % in the treated group, p < 0.05) and no evolution for
medium size vessels (Fig. 4). Interestingly, the vascular
volume decrease did not induce a global increase in HIF1
Fig. 2 Evolution of PET radiotracer uptakes. a Representative images of a tumour-bearing mouse injected with [18F]FDG prior to treatment (left)
and after 5 days (right) of sunitinib (lower part) or DMSO (upper part) administration (B: bladder, H: heart, T: tumour). b Tumour [18F]FDG SUV evo-
lution for both 5 day-treated (n = 4) and control (n = 3) groups. c PET longitudinal images of a grafted mice injected with [18F]FMISO before treatment
(left) and after 6 days (right) of treatment with sunitinib (bottom) or DMSO only (top) (I: intestine, T: tumour). d Tumour [18F]FMISO uptake evolution
for both 6 day-treated (n = 3) and control (n = 3) groups
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alpha protein expression (Figs. 3b and 5a-b). On the con-
trary, sunitinib therapy led to a twofold reduction of HIF1
alpha labelling, from 11.5 ± 1.0 % (n = 3) in control tu-
mours to 5.7 ± 3.5 % in treated ones (n = 4, p < 0.05).
TUNEL labelling revealed a high induction of apoptosis
by a factor of 17.7. Indeed, in nutrient supplied expanding
tumours, very low programmed cell death was observed,
representing 4.1 ± 0.3 % in volume (n = 3), while this value
was 72.6 ± 10.7 % in treated tumours (n = 4, p < 0.001)
(Figs. 3c and 5c-d). A mean pool of 1339 ± 248 cells per
mm3 of tumour (n = 3) were over-expressing Ki-67 in
non-treated tumours and the therapeutic agent reduced
this population to 730 ± 334 proliferating cells per mm3
(n = 4, p < 0.05). This represents a 1.8 fold reduction of the
tumour proliferation process (Figs. 3d and 5e-f). Tumours
grown in the control conditions presented a mean density
of 933 ± 212 macrophage cells (F4/80 positive) per mm3
of viable tumour tissue (n = 3). In the sunitinib treated
mice, this value was at 546 ± 169 macrophages per mm3
(n = 4) (Figs. 3e and 5g-h) (p < 0.05 compared to the con-
trol mice). Finally, GLUT1 whole tumour expression was
enhanced by a factor of 2.57 in the sunitinib treated group
when compared to control (Figs. 3f and 5i-j). Indeed,
transporter labelling represented 15.5 ± 2.6 % of control
hematoxylin volume (n = 3), and reached 40.0 ± 12.3 %
after the 9 days-long treatment (n = 4, p < 0.05).
Impact of sunitinib administration on the metastatic
dissemination in lungs
In set A, with a primary tumour growth duration of
30 days, comprising a 9-day sunitinib or DMSO adminis-
tration, no lung metastasis was detected 60 days after
tumour resection in the treated (n = 4) and control (n = 3)
groups. In set B with a 39 days tumour growth duration,
including 14 days of sunitinib or DMSO treatment, the
incidence of lung metastasis was of 50 % in the treated (n
= 4) and control (n = 4) groups (Fig. 6).
Discussion
With an ER+/− PR+/− HER2+ status and a luminal tran-
scriptomic signature, the PyMT model is considered to
mimic human luminal B (HER2-positive) breast cancers
[23–25]. The monitoring of mouse body weights during
Fig. 3 Biomarker quantification by digital microscopy. Each column corresponds to a labelling: a CD31, b HIF1 alpha, c TUNEL, d Ki-67, e F4/80,
f GLUT1. Representative control and 9 day-treated tissues are displayed on first and second rows respectively. The third row presents the associated
values. In bright field images, the biomarker of interest is labelled in brown and nuclei are counterstained in blue. In fluorescence images, TUNEL
labelling is represented in green and nuclei are counterstained in blue
Fig. 4 Sunitinib effect on blood vessel size. Comparison of the
proportion of small, medium and large vessels between the control
and treated groups (set A of mice)
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the sunitinib administration phases revealed no significant
variation by comparison to control groups, which suggests
that the drug, when administered at 40 mg/kg per os, had
acceptable toxicity on this model. The 9-day sunitinib
treatment induced a significant regression of the tumour
volume and a 14 day-treatment duration further reduced
the tumour volumes when compared to their respective
controls. These results are consistent with those reported
by Bousquet [13] and Abrams [15] regarding the luminal
mammary cancer responsiveness to sunitinib.
Fig. 5 Whole tumour slide imaging. HIF1 alpha: (a) in control tumours, the HIF1alpha expression is mainly located inside heaps of high cellularity
(b) in treated ones, the labelling is weaker, globally as necrotic regions get larger, and even locally inside living cell islets. TUNEL: (c) control
section with low level of apoptosis (d) highly apoptotic sunitinib-treated tumour. Ki-67: (e) proliferating cell density remains at a relatively low
level in control tumours, whereas (f) in treated ones, necropsied areas get larger but the density of Ki-67 positive cells increases in the remaining
living cell islets. F4/80: (g) in controls, the highest TAMs density is encountered at the interface of tumour and necrotic regions; (h) in treated
tumours, TAMs tend to relocate at the tumour external edges. GLUT1: (i) in control conditions, necrotic areas are the place of high GLUT1 expression;
(j) under sunitinib treatment, necropsied areas are larger and GLUT1 expression changed accordingly
Fig. 6 Lung metastasis incidence according to the primary tumour growth duration in control and treated groups. The percentage of lungs
bearing metastasis is plotted against the delay between tumour implantation and resection. At 30 days, no lung metastasis is present in treated
(n = 4) and control (n = 3) groups (set A). At 39 days, metastases are detected in half the lungs in both the 14 day-sunitinib treated group (n = 4)
and the corresponding control group (n = 4) (set B)
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The high efficiency of sunitinib on the MMTV-PyMT
model by comparison to TNBC models might be partly
explained by its dependency to particular pathways acti-
vated by the middle-T oncogene. Indeed, the middle-T
antigen was shown to act through co-optation of several
transduction pathways including: i) the protein phos-
phatase 2A (PP2A) activating the cytosolic tyrosine
kinases (PTK) of the Src family (Src, Fyn, Yes), ii) the
phospholinositide 3-kinase (PI3K) activating the Akt/
mTOR cell-survival pathway, iii) the mitogen-activated
protein kinases (MAPK/ERK) pathway through recruit-
ment of the Shc adapter protein and iv) the phospho-
lipase Cγ1 (PLC-γ) pathway inducing the protein kinase
C (PKC) activation and a cytosolic Ca2+ concentration
increase [26, 27]. As highlighted in Additional file 3, su-
nitinib is known to interact with the Src family cytosolic
tyrosine kinases and with more than 10 tyrosine kinase
membrane receptors that participate in the regulation of
the MAPK/ERK and PI3 kinase pathways. As recently
demonstrated on a medulloblastoma model, this drug
might also repress these two signalling cascades through
the induction of PTEN expression [28].
In addition to the decrease in tumour size, the vascular
network evaluation demonstrated that sunitinib impacts
vascular density and maturity. Moreover, the treated tu-
mours were characterised by a higher level of apoptosis by
comparison to controls. Previously, this multi-kinase in-
hibitor has already been shown to present in vitro and in
vivo anti-angiogenic effects as well as direct pro-apoptotic
properties [29, 30]. Regarding TAMs, their density was
slightly reduced under sunitinib treatment versus control.
As recently reviewed, TAMs roles are many and include
the promotion of neo-angiogenesis, tumour immune eva-
sion and metastatic behaviour [31]. To our knowledge our
study is the first to evaluate the therapy response to suniti-
nib of primary tumours in a mammary cancer model
using [18F]FDG or [18F]FMISO PET. The closest related
work describes a [18F]FDG PET monitoring of the suniti-
nib response on lung metastases in a 4T1 intravenously
induced metastatic model [32] and showed an increased
[18F]FDG signal in the lungs of the sunitinib-treated mice
compared to the control mice, which correlated with an
enhanced seeding of lung metastases associated with suni-
tinib administration. In our [18F]FDG PET data, the mean
SUV increased during the 5 day-tumour growth in the
control group, whereas it remained stable in the treated
tumours. We checked that the stable [18F]FDG uptake in
treated tumours that were concomitantly decreasing in
size was not due to partial volume effect (PVE) [33] and
found that PVE alone could not explain our observations.
The uptake mechanism of [18F]FDG has been previously
studied emphasizing the role of the GLUT protein family
[34]. In our work, we only measured GLUT1 expression
and showed that sunitinib increased the presence of this
transporter. The associated lack of increase in apparent
[18F]FDG uptake in sunitinib-treated tumours might be at
least partly explained by the lower levels in vascularisation,
TAM infiltration and cell viability in sunitinib treated by
comparison to control tumours. Yet, the overall conclu-
sion is therefore that [18F]FDG PET evidenced the re-
sponse to sunitinib treatment in this tumour model.
In our [18F]FMISO PET scans, randomization did not
yield two perfectly equivalent groups regarding the hyp-
oxia levels as expressed in SUV. Nevertheless, the un-
treated tumours remained stable in hypoxia over the
treatment course, whereas the sunitinib administration
tended to reduce hypoxia, although the difference was not
significant in our small sample. Therefore, despite the
reduction in blood supply, the treated tumours did not
become more hypoxic than before the sunitinib adminis-
tration. This might seem paradoxical as the sunitinib-
induced anti-angiogenic effects are often associated with
an increase in hypoxia due to the tumour starvation in
nutrients. This enhanced hypoxia phenomenon has for
instance been described by Welti et al. [32] and contri-
butes to explain the sunitinib efficacy on the preclinical
models. In our case, even in absence of enhanced hypoxia,
we observed a huge increase of the apoptotic level in the
treated tumours compared to the control ones. As ex-
plained above, the sunitinib is known to repress many cell
survival pathways that are over-activated by the middle-T
oncoprotein, and to present pro-apoptotic properties on
tumour cells [30]. This supports the idea that the tumour
cell apoptosis observed in our model might be mainly in-
duced by the direct pro-apoptotic properties of sunitinib,
owing to its multi-kinase inhibitor activity. Indeed, since
more apoptosis occurred in the sunitinib-treated tumours
compared to the control ones, the drug induced tumour
regression, which finally could explain the absence of en-
hanced hypoxia even in a reduced angiogenesis context.
The HIF1 alpha protein has a central role in the cellular
adaptation process under a stressful hypoxic environment.
Its regulation has been extensively reviewed [35]. Here the
mild, but not statistically significant, decrease of tumour
hypoxia observed in the sunitinib group was concomitant
with a reduced level of HIF1 alpha expression in sunitinib
tumours compared to control ones. [18F]FMISO PET
therefore appeared useful to characterise the hypoxia level
inside the tumours, and also to unveil the preferential way
of action of the drug on this model.
Interestingly, under sunitinib treatment, apoptosis was
highly increased by a factor of 17.7 whereas Ki-67-
positive cell number decreased only by a factor of 1.8
when compared with the control group. Areas of prolif-
erating cells were reduced but the Ki-67 marker was
denser in the remaining living cell islets. Thus, we
hypothesize that a resistance mechanism of a few cancer
cells to sunitinib might act through an induction of their
Thézé et al. BMC Cancer  (2015) 15:534 Page 8 of 10
cell-division cycle. Moreover, two recent publications
proved that one of the effects of this drug on TNBC
xenograft models is to increase the cancer stem cells
(CSCs) population [36] by generating intra-tumoral hyp-
oxia [37]. Further investigations might tell whether with
no increased hypoxic level, as observed in our model,
the proliferating cell pool still displays a few typical
CSCs markers. Those cells are indeed of major import-
ance as they present enhanced epithelial-mesenchymal
transition properties and thus high metastatic potential
[38]. Their promotion under sunitinib treatment might
at least partly explain its disappointing efficiency on
several models of metastasis [32, 39]. In our work, the
9 day-treated set A of mice did not allow us to study the
effect of the drug on the metastatic process. Comparing
the 14 day-treated group against controls (set B) im-
planted for 39 days, the treatment did not appear to im-
pact the incidence of lung metastases. Further molecular
characterisation of this sunitinib-resistant cellular pool is
required to specifically target them, for instance by com-
bining sunitinib treatment with a c-Met inhibition strat-
egy using crizotinib [40].
Conclusion
We showed that the luminal B (HER2-positive) type
PyMT model was particularly sensitive to sunitinib com-
pared to other preclinical breast cancer models, such as
TNBC models that have been extensively used to study
the effects of this drug. Our histology, [18F]FDG PET and
[18F]FMISO PET imaging results suggest that in addition
to its anti-angiogenic effects, the sunitinib efficacy on
this model is mostly due to its direct pro-apoptotic
properties.
Additional files
Additional file 1: General diagram for the CellProfiler pipeline
dedicated to image segmentation of GLUT1, HIF1 alpha, KI67 and
F4/80 labelled tissue slides. This example displays the step-by-step
image processing of a tumour tissue labelled for the F4/80 antigen. The
modules used in the pipeline are noted in bold. The image names
appear in italic by the image side.
Additional file 2: CellProfiler pipeline for vessel segmentation and
clustering in CD31 labelled tissue slides. The above example displays
the step-by-step image processing of a tumour tissue labelled for the
CD31 antigen. The modules used in the pipeline are noted in bold. The
image names appear in italic by the image side.
Additional file 3: List of the main known high affinity targets for
sunitinib. Sunitinib interaction partners were determined using a
semi-quantitative affinity chromatography method followed by LC/MS
analysis. Data collected from Bairlein et al. [29].
Abbreviations
[18F]FDG: 2-deoxy-2-[18F]fluoro-D-glucose; [18F]FMISO: [18F]fluoromisonidazole;
%ID/g: Percent of injected dose per gram; 2D-OSEM: Two dimensional
ordered-subset expectation maximization; CSCs: Cancer stem cells; DAB: 3-3'–
diamino-benzidine; DAPI: 4',6'-diamidino-2-phenylindole; DMSO: Dimethyl
sulfoxyde; ER: Estrogen receptor; GLUT1: Glucose transporter 1; HER2: Human
epidermal growth factor receptor 2; HIF1 alpha: Hypoxia induced factor 1
alpha; MMTV: Mouse mammary tumour virus; NS: Not significant;
ORR: Overall response rate; PET: Positron emission tomography;
PMID: Pubmed-indexed for MEDLINE; PR: Progesterone receptor; PVE: Partial
volume effect; PyMT: Polyoma virus middle T; qRT-PCR: Quantitative real time
polymerase chain reaction; RNA: Ribonucleic acid; ROIs: Regions of interest;
SD: Standard deviation; SUV: Standardized uptake value; TAMs: Tumour-
associated macrophages; TNBC: Triple negative breast cancer; TSA: Tyramide
signal amplification; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick
end labelling; TZM: Trastuzumab.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BThézé contributed to design the study, carried out the animal model set
up, the therapy model monitoring, the histochemistry experiments, and the
analyses led by digital microscopy and qRT-PCR. He performed the statistical
analyses and drafted the manuscript. NB participated in the therapy model
monitoring, and carried out the PET experiments and related image analyses.
AB participated in model monitoring and PET experiments. SB participated in
tissue sample preparation for histochemistry. BK carried out [18F]FMISO
radiosynthesis and its quality control. IB participated to data analyses and
interpretation, particularly those obtained by PET imaging, and helped to
draft and to correct the manuscript. BTavitian contributed to design the
study, provided funding and helped to draft the manuscript. RB contributed
to design the study, participated in its coordination, and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This research was funded by the “Institut National du Cancer (INCA)” under
grant agreement n° PL 051/RPT06018LLP.
Author details
1Laboratoire Imagerie Moléculaire In Vivo (IMIV, UMR 1023 Inserm/CEA/
Université Paris Sud - ERL 9218 CNRS, CEA/I²BM/SHFJ, 4 place du Général
Leclerc, 91400 Orsay, France. 2Animal Genetics and Integrative Biology,
INRA-AgroParisTech, UMR 1313, Jouy-en-Josas, France. 3Laboratory of
Radiobiology and Genomics Studies, CEA, DSV, IRCM, SREIT, Jouy-en-Josas,
France. 4Inserm U970, Université Paris Descartes, Paris, France.
Received: 8 January 2015 Accepted: 13 July 2015
References
1. Robert F, Sandler A, Schiller JH, Liu G, Harper K, Verkh L, et al. Sunitinib in
combination with docetaxel in patients with advanced solid tumors: a phase I
dose-escalation study. Cancer Chemother Pharmacol. 2010;66:669–80.
2. Wildiers H, Fontaine C, Vuylsteke P, Martens M, Canon JL, Wynendaele W, et
al. Multicenter phase II randomized trial evaluating antiangiogenic therapy
with sunitinib as consolidation after objective response to taxane
chemotherapy in women with HER2-negative metastatic breast cancer.
Breast Cancer Res Treat. 2010;123:463–9.
3. Mayer EL, Dhakil S, Patel T, Sundaram S, Fabian C, Kozloff M, et al. SABRE-B:
an evaluation of paclitaxel and bevacizumab with or without sunitinib as
first-line treatment of metastatic breast cancer. Ann Oncol. 2010;21:2370–6.
4. Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, et al.
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line
treatment of patients with advanced breast cancer: a phase iii, randomized,
open-label trial. Clinical Breast Cancer. 2011;11:82–92.
5. Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, et al.
First-line treatment of advanced breast cancer with sunitinib in combination
with docetaxel versus docetaxel alone: results of a prospective, randomized
phase iii study. JCO. 2012;30:921–9.
6. Barrios CH, Liu M-C, Lee SC, Vanlemmens L, Ferrero J-M, Tabei T, et al.
Phase III randomized trial of sunitinib versus capecitabine in patients with
previously treated HER2-negative advanced breast cancer. Breast Cancer Res
Treat. 2010;121:121–31.
7. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al.
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase
Thézé et al. BMC Cancer  (2015) 15:534 Page 9 of 10
inhibitor, in patients with metastatic breast cancer previously treated with
an anthracycline and a taxane. JCO. 2008;26:1810–6.
8. Cardoso F, Canon J-L, Amadori D, Aldrighetti D, Machiels J-P, Bouko Y, et al.
An exploratory study of sunitinib in combination with docetaxel and
trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
The Breast. 2012;21:716–23.
9. Bachelot T, Garcia-Saenz JA, Verma S, Gutierrez M, Pivot X, Kozloff MF, et al.
Sunitinib in combination with trastuzumab for the treatment of advanced
breast cancer: activity and safety results from a phase II study. BMC Cancer.
2014;14:166.
10. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
J Clin Oncol. 2009;27:1160–7.
11. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer.
Mol Oncol. 2011;5:5–23.
12. Eroles P, Bosch A, Alejandro Pérez-Fidalgo J, Lluch A. Molecular biology in
breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev.
2012;38:698–707.
13. Bousquet G, Varna M, Ferreira I, Wang L, Mongiat-Artus P, Leboeuf C, et al.
Differential regulation of sunitinib targets predicts its tumor-type-specific
effect on endothelial and/or tumor cell apoptosis. Cancer Chemother
Pharmacol. 2013;72:1183–93.
14. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research.
Breast Cancer Res. 2011;13:215.
15. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, et al.
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single
agent and in combination with “standard of care” therapeutic agents for
the treatment of breast cancer. Mol Cancer Ther. 2003;2:1011–21.
16. Eades G. Breast cancer MicroRNAs: signaling networks and clinical
applications. In: López-Camarillo C, Marchat LA, editors. MicroRNAs in
Cancer. Boca Raton, FL: CRC Press; 2013. p. 1–42.
17. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics.
2012;6:289–97.
18. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 Index,
HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. J Natl
Cancer Inst. 2009;101:736–50.
19. Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, et al.
Accelerated preclinical testing using transplanted tumors from genetically
engineered mouse breast cancer models. Clin Cancer Res. 2007;13:2168–77.
20. Jones TR, Kang IH, Wheeler DB, Lindquist RA, Papallo A, Sabatini DM, et al.
Cell profiler analyst: data exploration and analysis software for complex
image-based screens. BMC Bioinformatics. 2008;9:482.
21. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of
image analysis. Nat Meth. 2012;9:671–5.
22. Cuevas BD, Winter-Vann AM, Johnson NL, Johnson GL. MEKK1 controls
matrix degradation and tumor cell dissemination during metastasis of
polyoma middle-T driven mammary cancer. Oncogene. 2006;25:4998–5010.
23. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al.
Identification of conserved gene expression features between murine
mammary carcinoma models and human breast tumors. Genome Biol.
2007;8:R76.
24. Nakasone ES, Askautrud HA, Kees T, Park J-H, Plaks V, Ewald AJ, et al.
Imaging tumor-stroma interactions during chemotherapy reveals
contributions of the microenvironment to resistance. Cancer Cell.
2012;21:488–503.
25. Fluck MM, Schaffhausen BS. Lessons in signaling and tumorigenesis from
polyomavirus middle T antigen. Microbiol Mol Biol Rev. 2009;73:542–63.
26. Qiu TH, Chandramouli GVR, Hunter KW, Alkharouf NW, Green JE, Liu ET.
Global expression profiling identifies signatures of tumor virulence in
MMTV-PyMT-transgenic mice correlation to human disease. Cancer Res.
2004;64:5973–81.
27. Schaffhausen BS, Roberts TM. Lessons from polyoma middle T antigen on
signaling and transformation: A DNA tumor virus contribution to the war
on cancer. Virology. 2009;384:304–16.
28. Abouantoun TJ, Castellino RC, MacDonald TJ. Sunitinib induces PTEN
expression and inhibits PDGFR signaling and migration of medulloblastoma
cells. J Neuro Oncol. 2010;101:215–26.
29. Bairlein M. Characterization of the small molecule kinase inhibitor SU11248
(Sunitinib, SUTENT) in vitro and in vivo: towards response prediction in
cancer therapy with kinase inhibitors. In: PhD thesis. Munich: Technical
University of Munich, Department of Genetics; 2010.
30. Young E, Miele L, Tucker KB, Huang M, Wells J, Gu J-W. SU11248, a selective
tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth
via targeting both tumor vasculature and breast cancer cells. Cancer Biol
Ther. 2010;10:703–11.
31. Olopade O. The role of tumor-associated macrophages in breast cancer
progression (Review). Int J Oncol. 2013;43:5–12.
32. Welti J, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, et al. Contrasting
effects of sunitinib within in vivo models of metastasis. Angiogenesis.
2012;15:623–41.
33. Soret M, Bacharach SL, Buvat I. Partial-Volume Effect in PET Tumor Imaging.
J Nucl Med. 2007;48:932–45.
34. Krzeslak A, Wojcik-Krowiranda K, Forma E, Jozwiak P, Romanowicz H,
Bienkiewicz A, et al. Expression of GLUT1 and GLUT3 Glucose Transporters
in Endometrial and Breast Cancers. Pathol Oncol Res. 2012;18:721–8.
35. Koh MY, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come,
easy go. Trends Biochem Sci. 2008;33:526–34.
36. Chinchar E, Makey KL, Gibson J, Chen F, Cole SA, Megason GC, et al.
Sunitinib significantly suppresses the proliferation, migration, apoptosis
resistance, tumor angiogenesis and growth of triple-negative breast cancers
but increases breast cancer stem cells. Vasc Cell. 2014;6:12.
37. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et
al. Antiangiogenic agents increase breast cancer stem cells via the
generation of tumor hypoxia. Proc Nat Acad Sci. 2012;109:2784–9.
38. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al.
Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with
Metastatic Capacity and a Distinct Molecular Signature. Cancer Res.
2009;69:1302–13.
39. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS.
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor
of Tumor Angiogenesis. Cancer Cell. 2009;15:232–9.
40. Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG. HGF/c-Met
pathway is one of the mediators of sunitinib-induced tumor cell
type-dependent metastasis. Canc Lett. 2012;320:48–55.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thézé et al. BMC Cancer  (2015) 15:534 Page 10 of 10
